Clinical Trial Update: Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Upadacitinib for Primary Sjögren's Syndrome is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Primary Sjögren's Syndrome (pSS) | Phase 2 | Status: NOT_YET_RECRUITING